 Information Flow Chart
|
As the distinction between pharma and biotech blurs, so, too, does the distinction between investor relations (IR) and public
relations (PR) agencies serving those industries. The recent merger of PResence Euro RSCG and IR mainstay Noonan/Russo into
the newly named Noonan/Russo PResence Euro RSCG (NRP) may best represent the agency world's attempt to unify-and theoretically,
strengthen-its clients' financial, corporate, and product messages for a growing list of audiences. But most interesting may
be the role played by agencies' most important audience-the media-which finds itself in the middle of an unusual flow of information
fraught with potential conflicts of interest.
Freelance reporters are the "eyes and ears" of the Grassroots Research Group (GRG) of investment company Dresdner RCM, a part
of the giant German insurer Alliance, whose clients' assets are valued at nearly one trillion euros. Misha Derkavski, GRG's
director, says journalists have played a significant role in creating the company's healthcare analyst reports for nearly
20 years.
"They gather information simply by talking to knowledgeable sources who are not related to the financial industry," he explains.
"That includes practicing physicians, clinical investigators, and other healthcare providers."
Ian Vose, global director of research, uses a recent GRG study designed to assess the changing market dynamics for Genzyme's
renal disease treatment Renagel (sevelamer) to describe how the group adds value to analysts' investment advice."The drug's growth slowed a bit at the end of the fourth quarter," says Vose, "and there was some concern about whether that
was the beginning of a trend or just an anomaly. So we talked to nephrologists to see if they planned to use more or less
Renagel, if their use had plateaued, and how they felt about a competitor entering the market within the next year."
Vose, Derkavski, and Michael Dauchot, lead healthcare analyst at Dresdner, all say they go to great lengths to avoid journalistic
bias in designing surveys and reviewing reporters' results. But it's unlikely that reporters involved in GRG maintain objectivity
when they are bombarded by information from the very companies whose products they're assigned to research. Reporters' choices
of survey subjects-doctors and other prescribers who may have been influenced by corporate PR and marketing campaigns-may
be biased and may exclude subjects with different perspectives of the product or company.
Nevertheless, the Dresdner team says, trusted management contacts provide them with insights into companies that often reveal
problems and difficult issues. That doesn't mean it won't recommend investment in a company with problems. In fact, if a company
has a proven track record and its leadership has been honest and open about those problems, it may still fall into the "buy"
category.
Derkavski says that, by reconciling the views of doctors, managed care providers, and pharma companies, they can better assess
the complex interplay of forces affecting the industry. That philosophy, says NRP's executive vice-president and general manager
Nancy Rueth, captures the future of corporate and product communications in which the media is part of the process, not just
a target for information.